Synthesis of Ursolic Acid-based Hybrids: In Vitro Antibacterial,
Cytotoxicity Studies, In Silico Physicochemical and Pharmacokinetic
Properties

Vuyolwethu      Khwaza; Samson   Olaitan   Oselusi; Eric      Morifi; Mutshinyalo      Nwamadi; Kamogelo   S.   Hlope; Derek   Tantoh   Ndinteh; Thabe   Moses   Matsebatlela; Opeoluwa   Oyehan   Oyedeji; Blessing   Atim   Aderibigbe

doi:10.2174/0127724344272444231114103144

Abstract

Background: There is a critical need for the discovery of novel and effective antibacterial or anticancer molecules.

Objectives: Amine-linked ursolic acid-based hybrid compounds were prepared in good yields in the range of 60-68%.

Methods: Their molecular structures were successfully confirmed using different spectroscopic methods including ¹H/¹³C NMR, UHPLC-HRMS and FTIR spectroscopy. The in vitro cytotoxicity of some of these hybrid molecules against three human tumour cells, such as MDA-MB23, MCF7, and HeLa was evaluated using the MTT colorimetric method.

Result: Their antibacterial efficacy was evaluated against eleven bacterial pathogens using a serial dilution assay. Majority of the bacterial strains were inhibited significantly by compounds 17 and 24, with the lowest MIC values in the range of 15.3-31.25 μg/mL. Compound 16 exhibited higher cytotoxicity against HeLa cells than ursolic acid, with an IC₅₀ value of 43.64 g/mL.

Conclusion: The in vitro antibacterial activity and cytotoxicity of these hybrid compounds demonstrated that ursolic acid-based hybrid molecules are promising compounds. Further research into ursolic acid-based hybrid compounds is required.

« Previous Next »

Graphical Abstract

[1]
Xu B, Chu F, Zhang Y, et al. A series of new ligustrazine-triterpenes derivatives as anti-tumor agents: Design, synthesis, and biological evaluation. Int J Mol Sci  2015; 16(9): 21035-55.
 [http://dx.doi.org/10.3390/ijms160921035] [PMID: 26404253]

[2]
Khwaza V, Oyedeji OO, Aderibigbe BA. Ursolic acid-based derivatives as potential anti-cancer agents: an update. Int J Mol Sci  2020; 21(16): 5920.
 [http://dx.doi.org/10.3390/ijms21165920] [PMID: 32824664]

[3]
Xiao S, Wang Q, Si L, et al. Synthesis and anti-HCV entry activity studies of β-cyclodextrin-pentacyclic triterpene conjugates. ChemMedChem  2014; 9(5): 1060-70.
 [http://dx.doi.org/10.1002/cmdc.201300545] [PMID: 24623716]

[4]
Sathya S, Sudhagar S, Sarathkumar B, Lakshmi BS. EGFR inhibition by pentacyclic triterpenes exhibit cell cycle and growth arrest in breast cancer cells. Life Sci  2014; 95(1): 53-62.
 [http://dx.doi.org/10.1016/j.lfs.2013.11.019] [PMID: 24333132]

[5]
Shanmugam MK, Dai X, Kumar AP, Tan BKH, Sethi G, Bishayee A. Ursolic acid in cancer prevention and treatment: Molecular targets, pharmacokinetics and clinical studies. Biochem Pharmacol  2013; 85(11): 1579-87.
 [http://dx.doi.org/10.1016/j.bcp.2013.03.006] [PMID: 23499879]

[6]
Wolska KI, Grudniak AM, Fiecek B, Kraczkiewiczdowjat A, Kurek A. Antibacterial activity of oleanolic and ursolic acids and their derivatives. Cent Eur J Biol  2010; 5(5): 543-53.

[7]
Kazmi I, Rahman M, Afzal M, et al. Anti-diabetic potential of ursolic acid stearoyl glucoside: A new triterpenic gycosidic ester from Lantana camara. Fitoterapia  2012; 83(1): 142-6.
 [http://dx.doi.org/10.1016/j.fitote.2011.10.004] [PMID: 22051701]

[8]
Zhao J, Zheng H, Sui Z, et al. Ursolic acid exhibits anti-inflammatory effects through blocking TLR4-MyD88 pathway mediated by autophagy. Cytokine  2019; 123: 154726.
 [http://dx.doi.org/10.1016/j.cyto.2019.05.013] [PMID: 31302461]

[9]
Tohmé MJ, Giménez MC, Peralta A, Colombo MI, Delgui LR. Ursolic acid: A novel antiviral compound inhibiting rotavirus infection in vitro. Int J Antimicrob Agents  2019; 54(5): 601-9.
 [http://dx.doi.org/10.1016/j.ijantimicag.2019.07.015] [PMID: 31356859]

[10]
Ramachandran S, Prasad NR. Effect of ursolic acid, a triterpenoid antioxidant, on ultraviolet-B radiation-induced cytotoxicity, lipid peroxidation and DNA damage in human lymphocytes. Chem Biol Interact  2008; 176(2-3): 99-107.
 [http://dx.doi.org/10.1016/j.cbi.2008.08.010] [PMID: 18793624]

[11]
Liu MC, Yang SJ, Jin LH, et al. Synthesis and cytotoxicity of novel ursolic acid derivatives containing an acyl piperazine moiety. Eur J Med Chem  2012; 58: 128-35.
 [http://dx.doi.org/10.1016/j.ejmech.2012.08.048] [PMID: 23124210]

[12]
Rashid S, Dar BA, Majeed R, Hamid A, Bhat BA. Synthesis and biological evaluation of ursolic acid-triazolyl derivatives as potential anti-cancer agents. Eur J Med Chem  2013; 66: 238-45.
 [http://dx.doi.org/10.1016/j.ejmech.2013.05.029] [PMID: 23811086]

[13]
Kraljević TG, Harej A, Sedić M, et al. Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole–coumarin hybrids. Eur J Med Chem  2016; 124: 794-808.
 [http://dx.doi.org/10.1016/j.ejmech.2016.08.062] [PMID: 27639370]

[14]
Yusuf K, Sampath V, Umar S. Bacterial Infections and Cancer: Exploring this association and its implications for cancer Patients. Int J Mol Sci  2023; 24(4): 3110.
 [http://dx.doi.org/10.3390/ijms24043110] [PMID: 36834525]

[15]
Gatadi S, Gour J, Nanduri S. Natural product derived promising anti-MRSA drug leads: A review. Bioorg Med Chem  2019; 27(17): 3760-74.
 [http://dx.doi.org/10.1016/j.bmc.2019.07.023] [PMID: 31324564]

[16]
Khwaza V, Oyedeji OO, Aderibigbe BA, et al. Synthesis, antibacterial, and cytotoxicity evaluation of Oleanolic Acid-4-aminoquinoline based hybrid compounds. Recent Adv anti-infective drug Discov  2021; 16(2): 1-15.

[17]
Nguyen HT, Thi TA, Thi P, et al. A new approach for the synthesis of novel naphthoquinone chalcone hybrid compounds. Tetrahedron Lett  2021; 81: 153337.
 [http://dx.doi.org/10.1016/j.tetlet.2021.153337]

[18]
Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J  2018; 39(40): 3654-61.
 [http://dx.doi.org/10.1093/eurheartj/ehy420] [PMID: 30060044]

[19]
Sadaphal P, Chakraborty K, Jassim-AlMossawi H, et al. Rifampicin bioavailability in fixed-dose combinations for tuberculosis treatment: Evidence and Policy Actions. J Lung Health Dise  2019; 3(3): 9-15.
 [http://dx.doi.org/10.29245/2689-999X/2019/3.1155]

[20]
Wang P, Wang J, Guo T, Li Y. Synthesis and cytotoxic activity of the N-acetylglucosamine-bearing triterpenoid saponins. Carbohydr Res  2010; 345(5): 607-20.
 [http://dx.doi.org/10.1016/j.carres.2010.01.002] [PMID: 20116049]

[21]
Jin IJ, Ko YI, Kim YM, Han SK. Solubilization of oleanolic acid and ursolic acid by cosolvency. Arch Pharm Res  1997; 20(3): 269-74.
 [http://dx.doi.org/10.1007/BF02976156] [PMID: 18975163]

[22]
Wang Z, Barrows RD, Emge TJ, Knapp S. stereochemical aspects of T3P amidations. Org Process Res Dev  2017; 21(3): 399-407.
 [http://dx.doi.org/10.1021/acs.oprd.7b00046]

[23]
Montalbetti CAGN, Falque V. Amide bond formation and peptide coupling. Tetrahedron  2005; 61(46): 10827-52.
 [http://dx.doi.org/10.1016/j.tet.2005.08.031]

[24]
Anusionwu CG, Aderibigbe BA, Adeyemi SA, et al. Novel ferrocenylbisphosphonate hybrid compounds: Synthesis, characterization and potent activity against cancer cell lines. Bioorg Med Chem  2022; 58: 116652.
 [http://dx.doi.org/10.1016/j.bmc.2022.116652] [PMID: 35180594]

[25]
Bai KK, Yu Z, Chen FL, Li F, Li WY, Guo YH. Synthesis and evaluation of ursolic acid derivatives as potent cytotoxic agents. Bioorg Med Chem Lett  2012; 22(7): 2488-93.
 [http://dx.doi.org/10.1016/j.bmcl.2012.02.009] [PMID: 22370266]

[26]
Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov  2019; 18(1): 41-58.
 [http://dx.doi.org/10.1038/nrd.2018.168] [PMID: 30310233]

[27]
Yadav V, Talwar P. Biomedicine & Pharmacotherapy Repositioning of fl uoroquinolones from antibiotic to anti-cancer agents : An underestimated truth. Biomed Pharmacother  2019; 111: 934-46.
 [http://dx.doi.org/10.1016/j.biopha.2018.12.119] [PMID: 30841473]

[28]
Matthews H, Usman-Idris M, Khan F, Read M, Nirmalan N. Drug repositioning as a route to anti-malarial drug discovery: Preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate. Malar J  2013; 12(1): 359.
 [http://dx.doi.org/10.1186/1475-2875-12-359] [PMID: 24107123]

[29]
Ashley EA, Recht J, White NJ. Primaquine: The risks and the benefits. Malar J  2014; 13(1): 418.
 [http://dx.doi.org/10.1186/1475-2875-13-418] [PMID: 25363455]

[30]
Fernandes I, Vale N, de Freitas V, Moreira R, Mateus N, Gomes P. Anti-tumoral activity of imidazoquines, a new class of antimalarials derived from primaquine. Bioorg Med Chem Lett  2009; 19(24): 6914-7.
 [http://dx.doi.org/10.1016/j.bmcl.2009.10.081] [PMID: 19896373]

[31]
Perković I, Antunović M, Marijanović I, et al. Novel urea and bis -urea primaquine derivatives with hydroxyphenyl or halogenphenyl substituents: Synthesis and biological evaluation. Eur J Med Chem  2016; 124: 622-36.
 [http://dx.doi.org/10.1016/j.ejmech.2016.08.021] [PMID: 27614409]

[32]
Pavić K, Perković I, Gilja P, et al. Design, synthesis and biological evaluation of novel primaquinecinnamic acid conjugates of the amide and acylsemicarbazide type. Molecules  2016; 21(12): 1629.
 [http://dx.doi.org/10.3390/molecules21121629] [PMID: 27916811]

[33]
Vlainić J, Kosalec I, Pavić K, Hadjipavlou-Litina D, Pontiki E, Zorc B. Insights into biological activity of ureidoamides with primaquine and amino acid moieties. J Enzyme Inhib Med Chem  2018; 33(1): 376-82.
 [http://dx.doi.org/10.1080/14756366.2017.1423067] [PMID: 29363364]

[34]
Lanzafame G, Sarakha M, Fabbri D, Vione D. Degradation of methyl 2-aminobenzoate (methyl anthranilate) by H2O2/UV: Effect of inorganic anions and derived radicals. Molecules  2017; 22(4): 619.
 [http://dx.doi.org/10.3390/molecules22040619] [PMID: 28417930]

[35]
Sławiński J, Żołnowska B, Pirska D, Kędzia A, Kwapisz E. Synthesis and antibacterial activity of novel 4-chloro-2-mercaptobenzenesulfonamide derivatives. J Enzyme Inhib Med Chem  2013; 28(1): 41-51.
 [http://dx.doi.org/10.3109/14756366.2011.625024] [PMID: 22145585]

[36]
Zhang X. Syntheses, crystal structures and antibacterial activities of two antipyrine derivatives. J Chem Crystallogr  2011; 41(7): 1044-8.
 [http://dx.doi.org/10.1007/s10870-011-0042-6]

[37]
Wei W, Yan H, Zhao J, et al. Multi-omics comparisons of p -aminosalicylic acid (PAS) resistance in folC mutated and un-mutated Mycobacterium tuberculosis strains. Emerg Microbes Infect  2019; 8(1): 248-61.
 [http://dx.doi.org/10.1080/22221751.2019.1568179] [PMID: 30866779]

[38]
Minato Y, Thiede JM, Kordus SL, McKlveen EJ, Turman BJ, Baughn AD. Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance. Antimicrob Agents Chemother  2015; 59(9): 5097-106.
 [http://dx.doi.org/10.1128/AAC.00647-15] [PMID: 26033719]

[39]
Hatnapure GD, Keche AP, Rodge AH, Birajdar SS, Tale RH, Kamble VM. Synthesis and biological evaluation of novel piperazine derivatives of flavone as potent anti-inflammatory and antimicrobial agent. Bioorg Med Chem Lett  2012; 22(20): 6385-90.
 [http://dx.doi.org/10.1016/j.bmcl.2012.08.071] [PMID: 22981334]

[40]
Kim HS, Choi BS, Kwon KC, Lee SO, Kwak HJ, Lee CH. Synthesis and antimicrobial activity of squalamine analogue. Bioorg Med Chem  2000; 8(8): 2059-65.
 [http://dx.doi.org/10.1016/S0968-0896(00)00128-0] [PMID: 11003150]

[41]
Loncle C, Brunel JM, Vidal N, Dherbomez M, Letourneux Y. Synthesis and antifungal activity of cholesterol-hydrazone derivatives. Eur J Med Chem  2004; 39(12): 1067-71.
 [http://dx.doi.org/10.1016/j.ejmech.2004.07.005] [PMID: 15571868]

[42]
Blagbrough IS, Al-Hadithi D, Geall AJ. Cheno-, ursolic and deoxycholic acid spermine conjugates: Relative binding affinities for calf thymus DNA. Tetrahedron  2000; 56(21): 3439-47.
 [http://dx.doi.org/10.1016/S0040-4020(00)00265-9]

[43]
Jones SR, Kinney WA, Zhang X, Jones LM, Selinsky BS. The synthesis and characterization of analogs of the antimicrobial compound squalamine: 6β-hydroxy-3-aminosterols synthesized from hyodeoxycholic acid. Steroids  1996; 61(10): 565-71.
 [http://dx.doi.org/10.1016/S0039-128X(96)00114-6] [PMID: 8910969]

[44]
Freitag R. Synthetic Polymers for Biotechnology and Medicine. CRC press 2002.

[45]
Mallick S, Thuy LT, Lee S, Park JII, Choi JS. Liposomes containing cholesterol and mitochondria-penetrating peptide (MPP) for targeted delivery of antimycin A to A549 cells. Colloids Surf B Biointerfaces  2018; 161: 356-64.
 [http://dx.doi.org/10.1016/j.colsurfb.2017.10.052] [PMID: 29100129]

[46]
Fonkui TY, Ikhile MI, Ndinteh DT, Njobeh PB. Microbial activity of some heterocyclic Schiff bases and metal complexes: A review. Trop J Pharm Res  2019; 17(12): 2507-18.
 [http://dx.doi.org/10.4314/tjpr.v17i12.29]

[47]
Oselusi SO, Fadaka AO, Wyckoff GJ, Egieyeh SA. computational target-based screening of anti-mrsa natural products reveals potential multitarget mechanisms of action through peptidoglycan synthesis proteins. ACS Omega  2022; 7(42): 37896-906.
 [http://dx.doi.org/10.1021/acsomega.2c05061] [PMID: 36312373]

[48]
Sastry MG, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des  2013; 27(3): 221-34.
 [http://dx.doi.org/10.1007/s10822-013-9644-8] [PMID: 23579614]

[49]
Ibrahim RS, El-Banna AA. Network pharmacology-based analysis for unraveling potential cancer-related molecular targets of Egyptian propolis phytoconstituents accompanied with molecular docking and in vitro studies. RSC Advances  2021; 11(19): 11610-26.
 [http://dx.doi.org/10.1039/D1RA01390D] [PMID: 35423607]

[50]
O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform  2011; 3(1): 33.
 [http://dx.doi.org/10.1186/1758-2946-3-33] [PMID: 21982300]

[51]
Madrid PB, Sherrill J, Liou AP, Weisman JL, DeRisi JL, Guy RK. Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities. Bioorg Med Chem Lett  2005; 15(4): 1015-8.
 [http://dx.doi.org/10.1016/j.bmcl.2004.12.037] [PMID: 15686903]

[52]
Jama S, Nqoro X, Morifi E. 4-Aminosalicylic Acid-based Hybrid Compounds: Synthesis and in vitro Antiplasmodial Evaluation. Lett Drug Des Discov  2021; 18(3): 284-98.

[53]
Kahnt M, Hoenke S, Fischer L, Al-Harrasi A, Csuk R. Synthesis and cytotoxicity evaluation of DOTA-conjugates of ursolic acid. Molecules  2019; 24(12): 2254.
 [http://dx.doi.org/10.3390/molecules24122254] [PMID: 31212958]

[54]
Majidzadeh H, Araj-Khodaei M, Ghaffari M, et al. The combination of berberine and methotrexate enhances anti-cancer effects in HeLa cancer cell line: A morphological study. Ulum-i Daruyi  2021; 27(4): 536-42.
 [http://dx.doi.org/10.34172/PS.2021.12]

[55]
Bandyopadhyay M, Muthuirulan P. promising targets for prospective antibacterial therapy. EC Microbiol  2018; 14(6): 351-60.

[56]
Bachran D, Schneider S, Bachran C, et al. Epidermal growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human cervical carcinoma cells. Int J Cancer  2010; 127(6): 1453-61.
 [http://dx.doi.org/10.1002/ijc.25123] [PMID: 20020492]

[57]
Sevelda F, Mayr L, Kubista B, et al. EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance. J Exp Clin Cancer Res  2015; 34(1): 134.
 [http://dx.doi.org/10.1186/s13046-015-0251-5] [PMID: 26526352]

[58]
Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol  2018; 12(1): 3-20.
 [http://dx.doi.org/10.1002/1878-0261.12155] [PMID: 29124875]

[59]
Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat  2012; 136(2): 331-45.
 [http://dx.doi.org/10.1007/s10549-012-2289-9] [PMID: 23073759]

[60]
Burness ML, Grushko TA, Olopade OI. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: Promising clinical target or only a marker? Cancer J  2010; 16(1): 23-32.
 [http://dx.doi.org/10.1097/PPO.0b013e3181d24fc1] [PMID: 20164687]

[61]
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res  2007; 13(15): 4429-34.
 [http://dx.doi.org/10.1158/1078-0432.CCR-06-3045] [PMID: 17671126]

[62]
Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol  2022; 85: 253-75.
 [http://dx.doi.org/10.1016/j.semcancer.2022.04.002] [PMID: 35427766]

[63]
Pei Y, Zhang Y, Zheng K, et al. Ursolic acid suppresses the biological function of osteosarcoma cells. Oncol Lett  2019; 18(3): 2628-38.
 [http://dx.doi.org/10.3892/ol.2019.10561] [PMID: 31404298]

[64]
Jabeen M, Ahmad S, Shahid K, Sadiq A, Rashid U. Ursolic acid hydrazide based organometallic complexes: Synthesis, characterization, antibacterial, antioxidant, and docking studies. Front Chem  2018; 6: 1-14.

[65]
Oprean C, Mioc M, Csányi E, et al. Improvement of ursolic and oleanolic acids’ antitumor activity by complexation with hydrophilic cyclodextrins. Biomed Pharmacother  2016; 83: 1095-104.
 [http://dx.doi.org/10.1016/j.biopha.2016.08.030] [PMID: 27551755]

[66]
Luan T, Jin C, Jin CM, Gong GH, Quan ZS. Synthesis and biological evaluation of ursolic acid derivatives bearing triazole moieties as potential anti- Toxoplasma gondii agents. J Enzyme Inhib Med Chem  2019; 34(1): 761-72.
 [http://dx.doi.org/10.1080/14756366.2019.1584622] [PMID: 30836795]

[67]
da Silva M, Comin M, Duarte T, et al. Synthesis, antiproliferative activity and molecular properties predictions of galloyl derivatives. Molecules  2015; 20(4): 5360-73.
 [http://dx.doi.org/10.3390/molecules20045360] [PMID: 25816079]

[68]
He Q, Xiao F, Yuan Q, Zhang J, Zhan J, Zhang Z. Cannabinoid receptor 2: A potential novel therapeutic target for sepsis? Acta Clin Belg  2019; 74(2): 70-4.
 [http://dx.doi.org/10.1080/17843286.2018.1461754] [PMID: 29694303]

[69]
Althobiti HA, Zabin SA. New Schiff bases of 2-(quinolin-8-yloxy)acetohydrazide and their Cu(ii), and Zn(ii) metal complexes: Their in vitro antimicrobial potentials and in silico physicochemical and pharmacokinetics properties. Open Chem  2020; 18(1): 591-607.
 [http://dx.doi.org/10.1515/chem-2020-0085]

[70]
Neervannan S. Preclinical formulations for discovery and toxicology: Physicochemical challenges. Expert Opin Drug Metab Toxicol  2006; 2(5): 715-31.
 [http://dx.doi.org/10.1517/17425255.2.5.715] [PMID: 17014391]

[71]
Raj S, Sasidharan S, Dubey VK, Saudagar P. Identification of lead molecules against potential drug target protein MAPK4 from L. donovani: An in-silico approach using docking, molecular dynamics and binding free energy calculation. PLoS One  2019; 14(8): e0221331.
 [http://dx.doi.org/10.1371/journal.pone.0221331] [PMID: 31425543]

[72]
Souza HDS, de Sousa RPF, Lira BF, et al. Synthesis, in silico study and antimicrobial evaluation of new selenoglycolicamides. J Braz Chem Soc  2019; 30(1): 188-97.

[73]
Mehboob R. Neurokinin-1 Receptor as a potential drug target for COVID-19 treatment. Biomed Pharmacother  2021; 143: 112159.
 [http://dx.doi.org/10.1016/j.biopha.2021.112159] [PMID: 34536760]

[74]
Rhoades JA, Peterson YK, Zhu HJ, Appel DI, Peloquin CA, Markowitz JS. Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: A potential source of drug-drug interactions. Pharm Res  2012; 29(4): 972-82.
 [http://dx.doi.org/10.1007/s11095-011-0637-9] [PMID: 22161308]

[75]
Garnier A, Vykoukal J, Hubertus J, et al. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells. Int J Oncol  2015; 47(1): 151-60.
 [http://dx.doi.org/10.3892/ijo.2015.3016] [PMID: 25998227]

[76]
Markowska A, Antoszczak M, Markowska J, Huczyński A. Statins: Hmg-coa reductase inhibitors as potential anticancer agents against malignant neoplasms in women. Pharmaceuticals (Basel)  2020; 13(12): 422.
 [http://dx.doi.org/10.3390/ph13120422] [PMID: 33255609]

[77]
Kostrzewa T, Styszko J, Gorska-Ponikowska M, Sledzinski T, Kuban-Jankowska A. Inhibitors of protein tyrosine phosphatase PTP1B with anticancer potential. Anticancer Res  2019; 39(7): 3379-84.
 [http://dx.doi.org/10.21873/anticanres.13481] [PMID: 31262859]

[78]
Forooshani MK, Scarpitta R, Fanelli GN, Miccoli M, Naccarato AG, Scatena C. Is It time to consider the androgen receptor as a therapeutic target in breast cancer? Anticancer Agents Med Chem  2022; 22(4): 775-86.

[79]
Bagchi S, Rathee P, Jayaprakash V, Banerjee S. Farnesyl transferase inhibitors as potential anticancer agents. Mini Rev Med Chem  2018; 18(19): 1611-23.
 [http://dx.doi.org/10.2174/1389557518666180801110342] [PMID: 30068272]

[80]
Ranjbarnejad T, Saidijam M, tafakh M, Pourjafar M, Talebzadeh F, Najafi R. Garcinol exhibits antiproliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells. Hum Exp Toxicol  2017; 36(7): 692-700.
 [http://dx.doi.org/10.1177/0960327116660865] [PMID: 27481098]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0127724344272444231114103144	Print ISSN 2772-4344
Publisher Name Bentham Science Publisher	Online ISSN 2772-4352

Recent Advances in Anti-Infective Drug Discovery

Synthesis of Ursolic Acid-based Hybrids: In Vitro Antibacterial, Cytotoxicity Studies, In Silico Physicochemical and Pharmacokinetic Properties

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract